These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7628136)

  • 1. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients.
    Di Salvo TG; O'Gara PT
    Clin Cardiol; 1995 May; 18(5):285-90. PubMed ID: 7628136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use.
    Hassaballa HA; Balk RA
    Expert Opin Drug Saf; 2003 Nov; 2(6):543-7. PubMed ID: 14585064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haloperidol-induced torsade de pointes.
    O'Brien JM; Rockwood RP; Suh KI
    Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill.
    Metzger E; Friedman R
    J Clin Psychopharmacol; 1993 Apr; 13(2):128-32. PubMed ID: 8463445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Torsade de pointes and low-dose oral haloperidol.
    Jackson T; Ditmanson L; Phibbs B
    Arch Intern Med; 1997 Sep; 157(17):2013-5. PubMed ID: 9308514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Torsade de pointes associated with the administration of intravenous haloperidol.
    Hassaballa HA; Balk RA
    Am J Ther; 2003; 10(1):58-60. PubMed ID: 12522522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature.
    Lawrence KR; Nasraway SA
    Pharmacotherapy; 1997; 17(3):531-7. PubMed ID: 9165555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
    Meyer-Massetti C; Cheng CM; Sharpe BA; Meier CR; Guglielmo BJ
    J Hosp Med; 2010 Apr; 5(4):E8-16. PubMed ID: 20394022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
    Tisdale JE; Rasty S; Padhi ID; Sharma ND; Rosman H
    J Clin Pharmacol; 2001 Dec; 41(12):1310-8. PubMed ID: 11762558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation.
    Fongemie JM; Al-Qadheeb NS; Estes NA; Roberts RJ; Temtanakitpaisan Y; Ruthazer R; Devlin JW
    Pharmacotherapy; 2013 Jun; 33(6):589-97. PubMed ID: 23529904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery.
    Perrault LP; Denault AY; Carrier M; Cartier R; Bélisle S
    Can J Anaesth; 2000 Mar; 47(3):251-4. PubMed ID: 10730737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
    Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
    Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs.
    Izumi-Nakaseko H; Nakamura Y; Cao X; Wada T; Ando K; Sugiyama A
    Cardiovasc Toxicol; 2017 Jul; 17(3):319-325. PubMed ID: 27738880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review.
    Hunt N; Stern TA
    Psychosomatics; 1995; 36(6):541-9. PubMed ID: 7501784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient.
    Akers WS; Flynn JD; Davis GA; Green AE; Winstead PS; Strobel G
    Pharmacotherapy; 2004 Mar; 24(3):404-8. PubMed ID: 15040655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Torsade de pointes following intravenous haloperidol administration in a patient with complete heart block.
    Ginwalla M; Biblo LA; Paydak H
    WMJ; 2009 Feb; 108(1):48-50. PubMed ID: 19326637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.
    Tisdale JE; Kovacs R; Mi D; McCabe GP; Cariera BL; Sharma N; Rosman H
    Pharmacotherapy; 2007 Feb; 27(2):175-82. PubMed ID: 17253907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
    Muzyk AJ; Rayfield A; Revollo JY; Heinz H; Gagliardi JP
    Drug Saf; 2012 Jul; 35(7):547-53. PubMed ID: 22702639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unsafe use of intravenous haloperidol: evaluation of recommendation-concordant care in hospitalized elderly adults.
    Cheung D; Wolfe B; Wald H; Cumbler E
    J Am Geriatr Soc; 2013 Jan; 61(1):160-1. PubMed ID: 23311558
    [No Abstract]   [Full Text] [Related]  

  • 20. Torsade de pointes associated with the use of intravenous haloperidol.
    Wilt JL; Minnema AM; Johnson RF; Rosenblum AM
    Ann Intern Med; 1993 Sep; 119(5):391-4. PubMed ID: 8338292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.